{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:48:05Z","timestamp":1794862085512,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV019355"],"award-info":[{"award-number":["INV019355"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV019355"],"award-info":[{"award-number":["INV019355"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Philantropy; Supported by the Biosciences Initiative at the University of Michigan through a Mid-career Biosciences Faculty Achievement Award."},{"name":"NIH SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program -"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccination and prior infection elicit neutralizing antibodies targeting SARS-CoV-2, yet the quantitative relationship between serum antibodies and infection risk against viral variants remains uncertain, particularly in underrepresented regions. We investigated the protective correlation of pre-exposure serum neutralizing antibody levels, employing a panel of SARS-CoV-2 pseudoviruses (Omicron BA.1, Omicron BA.2, and ancestral D614G), and Spike-binding antibody levels, with symptomatic BA.1 or BA.2 SARS-CoV-2 infections and overall infection, in 345 household contacts from a SARS-CoV-2 household cohort study in Nicaragua. A four-fold increase in homotypic-neutralizing (e.g., BA.1-neutralizing vs. BA.1 exposure) titers was correlated with protection from symptomatic infections (BA.1 protection: 28% [95%CI 12\u201342%]; BA.2 protection: 43% [20\u201362%]), and ancestral-neutralizing titers were also correlated with protection from either variant, but only at higher average levels than homotypic. Mediation analyses revealed that homotypic and D614G-neutralizing antibodies mediated protection from infection and symptomatic infection both from prior infection and vaccination. These findings underscore the importance of monitoring variant-specific antibody responses and highlight that antibodies targeting circulating strains may be more predictive of protection from infection. Nevertheless, ancestral-strain-neutralizing antibodies remain relevant as a correlate of protection. Our study emphasizes the need for continued efforts to assess antibody correlates of protection.<\/jats:p>","DOI":"10.1038\/s41467-025-65235-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:13:13Z","timestamp":1763730793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-6173","authenticated-orcid":false,"given":"Jos\u00e9 Victor","family":"Zambrana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Shotwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-0801","authenticated-orcid":false,"given":"Hannah E.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Saborio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Plazaola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nery","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Balmaseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-149X","authenticated-orcid":false,"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-7877","authenticated-orcid":false,"given":"Aubree","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"65235_CR1","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","volume":"183","author":"T Zohar","year":"2020","unstructured":"Zohar, T. et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508\u201319.e12 (2020).","journal-title":"Cell"},{"key":"65235_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"65235_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2902.221422","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 Infection. Emerg. Infect. Dis. 29, 381\u2013388 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"65235_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"65235_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"65235_CR6","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"65235_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35768-3","volume":"14","author":"Y Fong","year":"2023","unstructured":"Fong, Y. et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 14, 331 (2023).","journal-title":"Nat. Commun."},{"key":"65235_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med 27, 2032\u20132040 (2021).","journal-title":"Nat. Med"},{"key":"65235_CR9","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol"},{"key":"65235_CR10","doi-asserted-by":"publisher","first-page":"e0266852","DOI":"10.1371\/journal.pone.0266852","volume":"17","author":"J Perry","year":"2022","unstructured":"Perry, J. et al. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One 17, e0266852 (2022).","journal-title":"PLoS One"},{"key":"65235_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u201386 e8 (2023).","journal-title":"Cell"},{"key":"65235_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"65235_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"65235_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52194-9","volume":"15","author":"D Cromer","year":"2024","unstructured":"Cromer, D. et al. Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates. Nat. Commun. 15, 8395 (2024).","journal-title":"Nat. Commun."},{"key":"65235_CR15","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41591-024-03131-2","volume":"30","author":"K Sun","year":"2024","unstructured":"Sun, K. et al. SARS-CoV-2 correlates of protection from infection against variants of concern. Nat. Med. 30, 2805\u20132812 (2024).","journal-title":"Nat. Med."},{"key":"65235_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMc2203985","volume":"387","author":"HE Maier","year":"2022","unstructured":"Maier, H. E. et al. Protection associated with previous SARS-CoV-2 infection in Nicaragua. N. Engl. J. Med 387, 568\u2013570 (2022).","journal-title":"N. Engl. J. Med"},{"key":"65235_CR17","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2666-5247(23)00012-5","volume":"4","author":"G Regev-Yochay","year":"2023","unstructured":"Regev-Yochay, G. et al. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe 4, e309\u2013e318 (2023).","journal-title":"Lancet Microbe"},{"key":"65235_CR18","doi-asserted-by":"crossref","unstructured":"Woudenberg, T. et al. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. Euro Surveill 28, 2200681 (2023).","DOI":"10.2807\/1560-7917.ES.2023.28.25.2200681"},{"key":"65235_CR19","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41591-024-02962-3","volume":"30","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y. et al. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children. Nat. Med 30, 1373\u20131383 (2024).","journal-title":"Nat. Med"},{"key":"65235_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36984-1","volume":"14","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. Correlates of protection and viral load trajectories in Omicron breakthrough infections in triple vaccinated healthcare workers. Nat. Commun. 14, 1577 (2023).","journal-title":"Nat. Commun."},{"key":"65235_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126308","volume":"42","author":"M Canetti","year":"2024","unstructured":"Canetti, M., Barda, N., Lustig, Y. et al. Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers. Vaccine 42, 126308 (2024).","journal-title":"Vaccine"},{"key":"65235_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55931-w","volume":"16","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat. Commun. 16, 759 (2025).","journal-title":"Nat. Commun."},{"key":"65235_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/cid\/ciae465","volume":"80","author":"Y Fong","year":"2025","unstructured":"Fong, Y. et al. Neutralizing antibody immune correlates for a recombinant protein vaccine in the COVAIL trial. Clin. Infect. Dis. 80, 223\u2013227 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"65235_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52348-9","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat. Commun. 15, 7954 (2024).","journal-title":"Nat. Commun."},{"key":"65235_CR25","doi-asserted-by":"crossref","unstructured":"Aleman, G. V. et al. Tracking the genetic diversity of SARS-CoV-2 variants in Nicaragua throughout the COVID-19 Pandemic. Sci. Rep. 15, 4817 (2025).","DOI":"10.1038\/s41598-024-84113-9"},{"key":"65235_CR26","doi-asserted-by":"crossref","unstructured":"Zambrana, J. V. et al. Comparative analysis of SARS-CoV-2 antibody responses across global and lesser-studied vaccines. Vaccines (Basel) 12, 326 (2024).","DOI":"10.3390\/vaccines12030326"},{"key":"65235_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00630-0","volume":"8","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. NPJ Vaccines 8, 36 (2023).","journal-title":"NPJ Vaccines"},{"key":"65235_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jinf.2023.07.007","volume":"87","author":"A Atti","year":"2023","unstructured":"Atti, A. et al. Antibody correlates of protection against Delta infection after vaccination: a nested case-control within the UK-based SIREN study. J. Infect. 87, 420\u2013427 (2023).","journal-title":"J. Infect."},{"key":"65235_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39816-4","volume":"14","author":"T Hertz","year":"2023","unstructured":"Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat. Commun. 14, 4575 (2023).","journal-title":"Nat. Commun."},{"key":"65235_CR30","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMc2209651","volume":"387","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N. Engl. J. Med. 387, 1333\u20131336 (2022).","journal-title":"N. Engl. J. Med"},{"key":"65235_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/clinchem\/hvaa029","volume":"66","author":"DKW Chu","year":"2020","unstructured":"Chu, D. K. W. et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66, 549\u2013555 (2020).","journal-title":"Clin. Chem."},{"key":"65235_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13074","volume":"17","author":"HE Maier","year":"2023","unstructured":"Maier, H. E. et al. SARS-CoV-2 infection-induced immunity and the duration of viral shedding: results from a Nicaraguan household cohort study. Influenza Other Respir. Viruses 17, e13074 (2023).","journal-title":"Influenza Other Respir. Viruses"},{"key":"65235_CR33","doi-asserted-by":"crossref","unstructured":"Tingley, D., Yamamoto, T., Hirose, K., Keele, L., Imai, K. mediation: R package for causal mediation analysis. J. Stat. Softw. 59, 1\u201338 (2014).","DOI":"10.18637\/jss.v059.i05"},{"key":"65235_CR34","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing, Vienna, Austria (2025). Available at: https:\/\/www.R-project.org\/."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65235-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:13:15Z","timestamp":1763730795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65235"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65235-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. has received institutional funding from Flu Lab and Open Philanthropy; personal honoraria from Hope College and the La Jolla Institute of Immunology; compensation for expert testimony from Berman and Simmons; and travel support from the Gates Foundation and the National Institutes of Health (NIH). A.G. has also served or serves in an advisory capacity to Janssen Pharmaceuticals and Sanofi Pasteur. D.D.H. co-founded TaiMed Biologics and RenBio, and he serves as a consultant for WuXi Biologics and Brii Biosciences and is a board director at Vicarious Surgical. All other authors declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10305"}}